Cargando…

COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases

BACKGROUND: COVID-19 has significantly affected patients with cancer and revealed unanticipated challenges in securing optimal cancer care across different disciplines. The European Society for Medical Oncology COVID-19 and CAncer REgistry (ESMO-CoCARE) is an international, real-world database, coll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, P., Tsourti, Z., Ribeiro, J., Castelo-Branco, L., de Azambuja, E., Gennatas, S., Rogado, J., Sekacheva, M., Šušnjar, S., Viñal, D., Lee, R., Khallaf, S., Dimopoulou, G., Pradervand, S., Whisenant, J., Choueiri, T.K., Arnold, D., Harrington, K., Punie, K., Oliveira, J., Michielin, O., Dafni, U., Peters, S., Pentheroudakis, G., Romano, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156988/ https://www.ncbi.nlm.nih.gov/pubmed/37285719 http://dx.doi.org/10.1016/j.esmoop.2023.101566

Ejemplares similares

LBA70 COVID-19 in cancer patients: Update from the joint analysis of ESMO-CoCARE, BSMO, PSMO international databases
por: Romano, E., et al.
Publicado: (2022)

COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)
por: Castelo-Branco, L., et al.
Publicado: (2022)

1567MO COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE)
por: Romano, E., et al.
Publicado: (2021)

237P Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: A joint analysis of OnCovid and ESMO-CoCARE registries
por: Cortellini, A., et al.
Publicado: (2022)

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries
por: Cortellini, Alessio, et al.
Publicado: (2022)

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future
por: Geukens, T., et al.
Publicado: (2022)

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017)

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020)

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies
por: Berghoff, A.S., et al.
Publicado: (2021)

ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib
por: Lambertini, M., et al.
Publicado: (2020)

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey
por: Banerjee, Susana, et al.
Publicado: (2018)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
por: Gyawali, B., et al.
Publicado: (2021)

“The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores
por: Cherny, N.I., et al.
Publicado: (2022)

Development and Validation of Positive Smoker Identity Questionnaire (PSmoQi): A New Instrument for Smoking Cessation Correlates
por: Ahmad, Mohd Hanief, et al.
Publicado: (2019)

ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit
por: Pentheroudakis, G., et al.
Publicado: (2022)

The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration
por: Banerjee, S., et al.
Publicado: (2021)

ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer
por: Catanese, Silvia, et al.
Publicado: (2020)

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
por: Curigliano, G., et al.
Publicado: (2020)

The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II
por: Lim, K.H.J., et al.
Publicado: (2021)

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
por: Cherny, N I, et al.
Publicado: (2016)

1561O The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series
por: Lim, K.H.J., et al.
Publicado: (2021)

The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series
por: Lim, K.H.J., et al.
Publicado: (2021)

LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration
por: Banerjee, S., et al.
Publicado: (2020)

PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023)

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on oncogene-addicted NSCLC
por: Lim, K.H.J., et al.
Publicado: (2020)

From ESMO 2022
por: Romero, Diana
Publicado: (2022)

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer
por: Kanesvaran, R., et al.
Publicado: (2022)

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
por: Morgan, Gilberto, et al.
Publicado: (2016)

ESMO pays tribute to Professor José Baselga
por: Peters, S., et al.
Publicado: (2021)

ESMO pays tribute to Professor José Baselga
por: Peters, S., et al.
Publicado: (2021)

11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
por: van Halteren, H.K., et al.
Publicado: (2022)

From ESMO TAT 2021
por: Killock, David
Publicado: (2021)

From the ESMO Congress 2021
por: Sidaway, Peter
Publicado: (2021)

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
por: Paluch-Shimon, Shani, et al.
Publicado: (2020)

ESMO presidential symposium wrap up: the ClarIDHy trial
por: Abou-Alfa, Ghassan K
Publicado: (2020)

Cost–benefit analysis of the CoCare intervention to improve medical care in long-term care nursing homes: an analysis based on claims data
por: Brühmann, Boris A., et al.
Publicado: (2022)

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
por: Im, S.-A., et al.
Publicado: (2023)

ESMO 2017—my personal highlights
por: Kiesewetter, Barbara, et al.
Publicado: (2018)

My personal highlights of ESMO 2016
por: Dediu, M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p8hl8lp822vaok9ophieq8pimh